Hashem O. Alsaab

2.9k total citations · 1 hit paper
22 papers, 2.2k citations indexed

About

Hashem O. Alsaab is a scholar working on Biomaterials, Molecular Biology and Oncology. According to data from OpenAlex, Hashem O. Alsaab has authored 22 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Biomaterials, 5 papers in Molecular Biology and 5 papers in Oncology. Recurrent topics in Hashem O. Alsaab's work include Nanoparticle-Based Drug Delivery (5 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Advanced Photocatalysis Techniques (4 papers). Hashem O. Alsaab is often cited by papers focused on Nanoparticle-Based Drug Delivery (5 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Advanced Photocatalysis Techniques (4 papers). Hashem O. Alsaab collaborates with scholars based in Saudi Arabia, United States and India. Hashem O. Alsaab's co-authors include Arun K. Iyer, Samaresh Sau, Ketki Bhise, Sushil K. Kashaw, Katyayani Tatiparti, Rami M. Alzhrani, Prashant Kesharwani, Rakesh Kumar Tekade, Mohd Cairul Iqbal Mohd Amin and Umesh Gupta and has published in prestigious journals such as Biomaterials, Scientific Reports and Journal of Controlled Release.

In The Last Decade

Hashem O. Alsaab

17 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome

2017 1.3k citations Hashem O. Alsaab, Samaresh Sau et al. Frontiers in Pharmacology profile →

Peers

Countries citing papers authored by Hashem O. Alsaab

Since Specialization

Citations

This map shows the geographic impact of Hashem O. Alsaab's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hashem O. Alsaab with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hashem O. Alsaab more than expected).

Fields of papers citing papers by Hashem O. Alsaab

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hashem O. Alsaab. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hashem O. Alsaab. The network helps show where Hashem O. Alsaab may publish in the future.

Co-authorship network of co-authors of Hashem O. Alsaab

This figure shows the co-authorship network connecting the top 25 collaborators of Hashem O. Alsaab. A scholar is included among the top collaborators of Hashem O. Alsaab based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hashem O. Alsaab. Hashem O. Alsaab is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Magnesiothermal reduction and doping strategies in engineered TiO2 for pharmaceutical degradation and CO2 conversion 2025 ·npj Clean Water ·Jianzhi Gao, Hashem O. Alsaab, Masoud Habibi Zare, Saeed Shirazian	0
2	Combined experimental and DFT study of tamoxifen adsorption on PEG-modified graphene oxide for enhanced drug delivery 2025 ·European Journal of Pharmaceutical Sciences ·Khaled Almansour, Hashem O. Alsaab, Mahboubeh Pishnamazi	0
3	CFD comparison of novel [emim][DCA] and [emim][MS] ionic liquids for the separation of CO2 greenhouse gas in the membrane contactor 2025 ·Scientific Reports ·Mahboubeh Pishnamazi, Hashem O. Alsaab, Mohammed Al‐Bahrani	0
4	Particular exosomal micro-RNAs and gastrointestinal (GI) cancer cells' roles: Current theories 2024 ·Experimental Cell Research ·(unknown), (unknown), (unknown), Hashem O. Alsaab	0
5	Synthesis of Novel Benzimidazole-Based Thiazole Derivatives as Multipotent Inhibitors of α-Amylase and α-Glucosidase: In Vitro Evaluation along with Molecular Docking Study 2022 ·Molecules ·Rafaqat Hussain, Shahid Iqbal, Mazloom Shah, Wajid Rehman, Shoaib Khan, Liaqat Rasheed, Fazal Rahim, Ayed A. Dera, (unknown), Eslam B. Elkaeed, Nasser S. Awwad, Majed A. Bajaber, Mohammed Issa Alahmdi, Hamad Alrbyawi, Hashem O. Alsaab	44
6	Optoelectronic, structural and morphological analysis of Cu3BiS3 sulfosalt thin films 2022 ·Results in Physics ·Tanzeela Fazal, Shahid Iqbal, Mazloom Shah, Qaiser Mahmood, Bushra Ismail, Hashem O. Alsaab, Nasser S. Awwad, Hala A. Ibrahium, Eslam B. Elkaeed	18
7	Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes 2021 ·Advanced Therapeutics ·Rami M. Alzhrani, Hashem O. Alsaab, (unknown), Ketki Bhise, Katyayani Tatiparti, (unknown), Samaresh Sau, Arun K. Iyer	13
8	Designing a novel visible-light-driven heterostructure Ni–ZnO/S-g-C₃N₄ photocatalyst for coloured pollutant degradation 2021 ·RSC Advances ·Ali Bahadur, Shahid Iqbal, Hashem O. Alsaab, Nasser S. Awwad, Hala A. Ibrahium	61
9	The Possible Relationship between the Abuse of Tobacco, Opioid, or Alcohol with COVID-19 2020 ·Healthcare ·Yusuf S. Althobaiti, (unknown), (unknown), (unknown), Hashem O. Alsaab, Mohammad Nasir Uddin	24
10	PDL-1 Antibody Drug Conjugate for Selective Chemo-Guided Immune Modulation of Cancer 2019 ·Cancers ·Samaresh Sau, (unknown), Hashem O. Alsaab, Ketki Bhise, Arun K. Iyer	46
11	A tumor multicomponent targeting chemoimmune drug delivery system for reprograming the tumor microenvironment and personalized cancer therapy 2018 ·Drug Discovery Today ·Samaresh Sau, Katyayani Tatiparti, Hashem O. Alsaab, Sushil K. Kashaw, Arun K. Iyer	19
12	Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment 2018 ·Journal of Controlled Release ·Samaresh Sau, Hashem O. Alsaab, Ketki Bhise, Rami M. Alzhrani, (unknown), Arun K. Iyer	125
13	Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages 2018 ·Biomaterials ·Hashem O. Alsaab, Samaresh Sau, Rami M. Alzhrani, Vino T. Cheriyan, Lisa Polin, Ulka N. Vaishampayan, Arun K. Rishi, Arun K. Iyer	65
14	CD44 directed nanomicellar payload delivery platform for selective anticancer effect and tumor specific imaging of triple negative breast cancer 2018 ·Nanomedicine Nanotechnology Biology and Medicine ·(unknown), Samaresh Sau, Hashem O. Alsaab, Arun K. Iyer	52
15	Tumor Multicomponent Targeting Polymer-Lipid Hybrid Nanoparticles To Overcome Drug Resistance In Renal Cell Carcinoma 2018 ·Human Biology ·Hashem O. Alsaab	2
16	Folic acid conjugated polymeric micelles loaded with a curcumin difluorinated analog for targeting cervical and ovarian cancers 2017 ·Colloids and Surfaces B Biointerfaces ·(unknown), Prashant Kesharwani, Hashem O. Alsaab, Samaresh Sau, Subhash Padhyé, Fazlul H. Sarkar, Arun K. Iyer	87
17	PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome breakdown → 2017 ·Frontiers in Pharmacology ·Hashem O. Alsaab, Samaresh Sau, Rami M. Alzhrani, Katyayani Tatiparti, Ketki Bhise, Sushil K. Kashaw, Arun K. Iyer	1288
18	Advances in antibody–drug conjugates: A new era of targeted cancer therapy 2017 ·Drug Discovery Today ·Samaresh Sau, Hashem O. Alsaab, Sushil K. Kashaw, Katyayani Tatiparti, Arun K. Iyer	135
19	Nanomedicine for Cancer Diagnosis and therapy: advancement, Success and structure–activity Relationship 2017 ·Therapeutic Delivery ·Ketki Bhise, Samaresh Sau, Hashem O. Alsaab, Sushil K. Kashaw, Rakesh Kumar Tekade, Arun K. Iyer	48
20	Recent advances in hyaluronic acid-decorated nanocarriers for targeted cancer therapy 2016 ·Drug Discovery Today ·(unknown), Hashem O. Alsaab, Prashant Kesharwani, Ketki Bhise, Mohd Cairul Iqbal Mohd Amin, Rakesh Kumar Tekade, Umesh Gupta, Arun K. Iyer	166

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact